spec sheet6 rows
Ispronicline traces its chemistry back to nicotine research originally funded by tobacco company R.J. Reynolds, which spun off its pharmaceutical research arm into Targacept in the late 1990s. The resulting compound was a partial agonist at alpha4beta2 neuronal nicotinic receptors, designed to capture nicotine's attention- and memory-enhancing effects without its addictive and cardiovascular baggage. AstraZeneca partnered with Targacept and pushed ispronicline (as AZD3480) into a Phase IIb dose-finding trial for mild-to-moderate Alzheimer's disease as well as separate studies for adult ADHD. The Alzheimer's trial, published in 2011, failed to show a robust cognitive benefit, and AstraZeneca discontinued the partnership around 2010-2011, part of a broader collapse of the nicotinic-receptor cognition-enhancement field that also claimed several competing programs.
- selective alpha4beta2 nicotinic partial agonism with characterized human pharmacokinetics and safety
- studied for both Alzheimer's-related cognitive impairment and adult ADHD
- designed specifically to avoid nicotine's addictive and cardiovascular liabilities
- improved attention and episodic memory after repeated dosing in an age-associated memory impairment trial
- brain-selective alpha4beta2 targeting meant to reduce off-target nicotinic side effects
- good tolerability profile across Phase I and early Phase II testing
- detectable EEG changes consistent with central nicotinic engagement
- nicotinic-agonist class effects (nausea, mild cardiovascular changes) reported in trial populations
- general nicotinic-agonist tolerability considerations (mild autonomic effects at higher exposures)
- Ispronicline's chemistry lineage runs back to nicotine research that R.J. Reynolds, the tobacco company, originally funded before spinning its pharmaceutical unit off as Targacept.
- In its earliest positive trial, ispronicline improved memory only with repeated ten-day dosing, not after a single dose, an unusual delayed-onset pattern for a nicotinic agonist.
Mechanism
Ispronicline is a partial at neuronal alpha4beta2 receptors, intended to enhance attention and working memory through selective nicotinic signaling while limiting the off-target and addictive effects of nicotine itself.
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Across two Phase 1 studies that pushed single doses from 2 mg up to 320 mg and ran 200 mg daily for ten days, ispronicline was well tolerated, with dizziness and headache the usual complaints and no clinically meaningful change in laboratory values, blood pressure or heart rate. That profile held up in the 567-patient Alzheimer's trial and in a small crossover study in adults with ADHD. Nothing accumulated over ten days of dosing. Long exposure was never studied, since development stopped in Phase 2, so use beyond a few months is uncharacterised.
History
Developed by Targacept starting in the early 2000s as TC-1734, then co-developed with AstraZeneca as AZD3480; showed positive Phase II results in age-associated memory impairment, but the subsequent SIROCCO Phase II trial in mild-to-moderate Alzheimer's disease failed to significantly beat placebo on the primary cognitive endpoint, and its FDA development status for Alzheimer's is now listed inactive.
Resources
This entry is here for reference.
Research
- 2006first citedPharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor p…
- 2011controlled trialEffects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase…
- 2021most recentNicotine-like discriminative and aversive effects of two α4β2-selective nicotine agonists, ispr…
- 1.Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study
- 2.Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers
- 3.Nicotine-like discriminative and aversive effects of two α4β2-selective nicotine agonists, ispronicline and metanicotine.
- 4.Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers
4 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is ispronicline the same as nicotine?
No. It is a selective partial agonist at alpha4beta2 nicotinic receptors, engineered to isolate nicotine's attention-related effects from its addictive and broader cardiovascular activity, though it shares nicotine's core receptor target.
Why did AstraZeneca stop developing ispronicline?
Its Phase IIb dose-finding trial in Alzheimer's disease, published in 2011, did not demonstrate a strong enough cognitive benefit to justify continuing into Phase III, leading the partnership with Targacept to end.
Is ispronicline the same drug as TC-1734 or AZD3480?
Yes, all three names refer to the same compound; TC-1734 was Targacept's original code name, and AZD3480 was assigned after AstraZeneca licensed it for co-development.
Why didn't ispronicline become an Alzheimer's drug?
Its pivotal SIROCCO trial in mild-to-moderate Alzheimer's disease failed to show a statistically significant improvement over placebo on the primary cognitive measure, even though earlier trials in healthy older adults had shown clearer benefits.
Limitations of the evidence
- Phase IIb Alzheimer's trial did not show a robust cognitive benefit over placebo
- no statistically significant primary-endpoint benefit in the SIROCCO Alzheimer's trial
- acute single dosing did not reproduce the cognitive benefits seen with repeated dosing
Adverse effects
- nicotinic-agonist class effects (nausea, mild cardiovascular changes) reported in trial populations
- general nicotinic-agonist tolerability considerations (mild autonomic effects at higher exposures)